Stephen R Saklad, Tiffany-Jade Kreys, Stephanie V. Phan
{"title":"Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia","authors":"Stephen R Saklad, Tiffany-Jade Kreys, Stephanie V. Phan","doi":"10.9740/MHC.2015.07.149","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"31 1","pages":"149-161"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/MHC.2015.07.149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
